COVID-19 Collection

Journal article

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Abstract:: Background
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) o... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Group, R. E. C. O. V. E. R. Y. C. (2024). Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8(3), 190–200.

MLA Style

Group, RECOVERY Collaborative. “Immunomodulatory Therapy in Children with Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial.” The Lancet Child & Adolescent Health, vol. 8, no. 3, 2024, pp. 190–200.

Chicago Style

Group, RECOVERY Collaborative. 2024. “Immunomodulatory Therapy in Children with Paediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a Randomised, Controlled, Open-Label, Platform Trial.” The Lancet Child & Adolescent Health 8 (3): 190–200.
Print

Access Document

Files:: RECOVERY_Collaborative_Group_2024_Immunomodulatory_therapy_in.pdf

(Preview, Version of record, pdf, 553.0KB, Terms of use)

Publisher copy:: 10.1016/s2352-4642(23)00316-4

Authors

+ RECOVERY Collaborative Group More by this author

Role:: Author

+ Wellcome Trust More from this funder

Funder identifier:: https://ror.org/029chgv08
Grant:: 215091/Z/18/Z

+ Gates Foundation More from this funder

Funder identifier:: https://ror.org/0456r8d26
Grant:: OPP1209135

+ Medical Research Council More from this funder

Funder identifier:: https://ror.org/03x94j517
Grant:: MC_PC_19056

+ Moh Family Foundation More from this funder

+ UK Research and Innovation Medical Research Council More from this funder

Publisher:: Elsevier
Journal:: The Lancet Child & Adolescent Health More from this journal
Volume:: 8
Issue:: 3
Pages:: 190-200
Place of publication:: England
Publication date:: 2024-01-22
Acceptance date:: 2023-11-17
DOI:: 10.1016/s2352-4642(23)00316-4
EISSN:: 2352-4650
ISSN:: 2352-4642
Pmid:: 38272046

Language:: English
Keywords:: RECOVERY Collaborative Group
Pubs id:: 1611469
Local pid:: pubs:1611469
Deposit date:: 2024-03-08
ARK identifier:: ark:/29072/ora_06d9a29db4f24508b382f5c9022d56fb

Terms of use

Copyright holder:: RECOVERY Collaborative Group
Copyright date:: 2024
Rights statement:: © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP